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Abstract
Background: It is largely unknown how frequently low-abundance HIV drug-resistant variants at levels under limit of
detection of conventional genotyping (,20% of quasi-species) are present in antiretroviral-experienced persons
experiencing virologic failure. Further, the clinical implications of low-abundance drug-resistant variants at time of
virologic failure are unknown.
Methodology/Principal Findings: Plasma samples from 22 antiretroviral-experienced subjects collected at time of virologic
failure (viral load 1380 to 304,000 copies/mL) were obtained from a specimen bank (from 2004–2007). The prevalence and
profile of drug-resistant mutations were determined using Sanger sequencing and ultra-deep pyrosequencing. Genotypes
were interpreted using Stanford HIV database algorithm. Antiretroviral treatment histories were obtained by chart review
and correlated with drug-resistant mutations. Low-abundance drug-resistant mutations were detected in all 22 subjects by
deep sequencing and only in 3 subjects by Sanger sequencing. In total they accounted for 90 of 247 mutations (36%)
detected by deep sequencing; the majority of these (95%) were not detected by standard genotyping. A mean of 4
additional mutations per subject were detected by deep sequencing (p,0.0001, 95%CI: 2.85–5.53). The additional low-
abundance drug-resistant mutations increased a subject’s genotypic resistance to one or more antiretrovirals in 17 of 22
subjects (77%). When correlated with subjects’ antiretroviral treatment histories, the additional low-abundance drug-
resistant mutations correlated with the failing antiretroviral drugs in 21% subjects and correlated with historical
antiretroviral use in 79% subjects (OR, 13.73; 95% CI, 2.5–74.3, p=0.0016).
Conclusions/Significance: Low-abundance HIV drug-resistant mutations in antiretroviral-experienced subjects at time of
virologic failure can increase a subject’s overall burden of resistance, yet commonly go unrecognized by conventional
genotyping. The majority of unrecognized resistant mutations correlate with historical antiretroviral use. Ultra-deep
sequencing can provide important historical resistance information for clinicians when planning subsequent antiretroviral
regimens for highly treatment-experienced patients, particularly when their prior treatment histories and longitudinal
genotypes are not available.
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Introduction
HIV genotyping technologies other than the conventional HIV
genotyping have been used to show that viral variants in an HIV-
infected person, whether acutely or chronically infected, are more
genetically diverse than previously appreciated by conventional
HIV genotyping assays [1–9]. Current genotyping assays are
based on population sequencing of reverse transcriptase -
polymerase chain reaction (RT-PCR) generated products of
HIV protease (PR) and reverse transcriptase (RT) genes. Although
this technology has been a major advancement in the under-
standing and management of HIV drug resistance in clinical
practice, a major limitation is the inability to detect low-
abundance drug-resistant mutations (DRMs) at levels ,20% of
the viral quasi-species [10,11]. Low-abundance drug-resistant HIV
variants can occur de novo through the extraordinary HIV genetic
diversity generated via highly error-prone replication [12] or as
the result of transmitted resistant strains that persist within an
infected individual [6,7,13]. Understanding the environments in
which low-abundance drug-resistant variants develop, how they
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6079evolve and impact treatment response are important areas that
require further investigations.
A growing number of studies have shown that low-abundance
DRMs can be detected in chronically-infected antiretroviral-naı ¨ve
individuals using ultra-sensitive allele-specific PCR assays or by
ultra-deep sequencing methods [8,14–17]. These studies show
that baseline low-abundance DRMs undetected by conventional
sequencing, in particular non-nucleoside reverse transcriptase
inhibitor (NNRTI) mutations, are associated with poor treatment
response in persons initiating antiretroviral therapy (ART). This
finding follows the Darwinian principle of ‘survival of the fittest’,
in that drug-resistant variants at low levels can out-compete wild-
type virus in presence of antiretroviral selection pressure and lead
to treatment failure. A common and clinically-relevant question
that clinicians ask is how often commercial HIV genotyping
underestimates the presence of low-abundance DRMs in
treatment-experienced patients being evaluated for virologic
failure, and whether unrecognized low-abundance DRMs can
contribute to virologic failure. In this study, we examine the
prevalence and patterns of low-abundance DRMs in antiretrovi-
ral-experienced subjects experiencing virologic failure using
standard Sanger sequencing and a new ultra-deep sequencing
method [9,16,18]. We characterize how the addition of low-level
DRMs affects the resistance burden in antiretroviral-experienced
subjects using the Stanford HIV drug resistance database
algorithm and describe the relationship of the low-abundance
DRMs to subjects’ failing antiretroviral drugs and their longitu-
dinal antiretroviral histories.
Materials and Methods
Study sample selection
Plasma samples from 22 different HIV-infected antiretroviral-
experienced subjects who had HIV genotype testing done for
virologic failure indication (viral loads ranging from 1380 to
304,000 copies/mL) were obtained from a specimen bank
collected between 2004–2007 from routine HIV care at Yale
New Haven Hospital and from an adherence-focused clinical
trial in Connecticut [19]. All samples were identified only by a
lab number during standard and ultra-deep sequencing analyses.
Once blinded drug resistance analyses were completed, chart
reviews of patients’ existing clinical information were performed,
and subjects’ antiretroviral treatment histories were merged with
resistance data. Antiretroviral histories from clinical trial subjects
(N=12) were obtained from the study’s existing electronic
database. The study met criteria for informed consent
exemption and was approved by Yale University School of
Medicine and University of Connecticut human investigation
committees.
Standard population genotyping analysis
Viral RNA was isolated from 140 ml of plasma samples using
QIAmp RNA Mini kit (QIAGEN, Valencia, CA). The extracted
RNA specimens were subjected to RT-PCR using SuperScript
III (Invitrogen, Carlsbad, CA) to make cDNAs. A PCR assay
previously described was used to amplify PR and RT genes
[20,21]. PCR amplicons were sequenced directly by population
sequencing using an ABI 3730 XL automated sequencing system
(Applied Biosystems, Foster City, CA). All amino acid positions
associated with antiretroviral resistance according to IAS-USA
2008 and Stanford HIV drug resistance database were evaluated
[22]. Nucleotide mixtures at drug-resistant sites were called if a
discriminate peak from baseline was observed in two independent
reactions.
Ultra-deep pyrosequencing analysis
The same volume of plasma (140 ml) and RNA extraction
protocol used for standard sequencing was used for deep
sequencing to allow for a direct comparison of the two methods.
Input HIV RNA was not measured for standard sequencing nor
ultra deep sequencing for this set of samples. It has been shown
that the stochastic effects of sampling variation become low when
the starting RNA copy number in a specimen is $1,000 (or
$10,000 HIV RNA copies/mL for an unextracted sample
considering a 10% RNA extraction efficiency) [9,23]. Thus for
samples with RNA copy numbers ,10,000 (#3, 9, 11, 16, 18,
and 22), ultra-deep sequencing identifies the proportion of
sequenced PCR amplicons containing the mutation and may
not represent the actual proportion of HIV variants in a plasma
sample.
Three gene-specific overlapping cDNA per sample were
generated and subjected to 40 cycles of PCR with FastStart HiFi
polymerase (Roche, Indianapolis, IN) to make eight partly
overlapping amplicons that cover the entire PR and the first
236 codons of RT genes. The amplicons were purified with
AMPure magnetic beads (Agencourt, Beverly, MA) and quanti-
tated by PicoGreen fluorescence (Invitrogen). After equimolar
pooling of all 8 amplicons per sample, clonal amplification on
beads was performed using reagents enabling sequencing in both
forward (kit II) and reverse (kit III) directions (Roche/454 Life
Sciences, Branford, CT). Kit II and III emulsions were pooled for
each sample before bead isolation. After enrichment of DNA-
containing beads, these were counted on a Multisizer3 Coulter
counter.
Approximately thirty-thousand beads per sample were
prepared for ultra-deep sequencing and loaded on a PicoTiter
plate fitted with a 16-lane gasket. Sequencing was performed on
a Genome Sequencer FLX (Roche/454 Life Sciences). An
average of 1700 reads per nucleotide position was obtained for
this set of samples, which allowed for accurate detection of
variants down to approximately 1% when viral load is .10,000
copies/mL. Ultra-deep sequencing reproducibility and level of
variant detection have been previously reported [9,18]. The
sensitivity of ultra-deep sequencing in its current platform for
detection of low-level viral variants at levels 0.1 to 1% has been
confirmed by used of standard cloning methods [9,18,24,25]. In
this study we reported a variant detection limit of $1% as
resistant variants at this level have been shown to be clinically
relevant [7,14–16].
Amplicon Variant Analyzer software was used to align all
amplicon sequence reads to a consensus sequence generated from
over 6000 sequences found in the Los Alamos HIV sequence
database for identification of all nucleotide changes of interest.
Further detailed of this technology can be found elsewhere
[9,16,18].
Statistical analysis
Paired Student T test was used to compare the mean number of
DRMs detected by ultra-deep versus standard sequencing in 22
samples for all mutations, nucleoside reverse transcriptase
inhibitor (NRTI) mutations, NNRTI mutations and protease
inhibitor (PI) mutations, respectively. All p values presented were
two tailed, and 95% confidence intervals were calculated and
reported in figure 1. Odds ratios were used to describe the
association of low-abundance DRMs and subjects’ current failing
antiretroviral versus historical antiretroviral drugs. Fisher exact
test was used to determine the statistical significance of the
association.
Minor HIV Resistant Variants
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DRMs that are not detected by standard sequencing but
detected using more sensitive technologies have been referred to as
‘‘minority’’ or ‘‘low-level’’ drug-resistant variants in the literature
[1–9]. For the purpose of discussion in this paper, we define ‘‘low-
abundance’’ DRMs as mutations detected at ,20% of viral quasi-
species and ‘‘high-abundance’’ DRMs as mutations detected at
$20% of viral quasi-species by ultra-deep sequencing.
Results
Comparison of ultra-deep vs. standard population
sequencing data
Low-abundance DRMs were detected in all 22 subjects by deep
sequencing and were unrecognized in 19 subjects by standard
sequencing. In total they accounted for 90 of the 247 mutations
(36%) detected by deep sequencing; the majority of these (95%)
were not detected by standard genotyping. A mean of 4 (ranging
from 1 to 10) additional mutations per subject were detected by
deep sequencing compared to standard sequencing (p,0.0001,
95%CI: 2.85–5.53). The differences in the numbers of DRMs
detected by the two methods remained statistically significant
when mutations were classified into NRTIs, NNRTIs, and PIs
(Figure 1).
DRMs that were detected at levels ,13% of viral quasi-species
by deep sequencing were not detected by standard sequencing in
this study. Ultra-deep sequencing identified all DRMs at levels
$20% that were detected by standard sequencing. By comparison,
standard sequencing detected only 152 of 157 (97%) DRMs at
levels $20% that were detected by deep sequencing. The high-
abundance mutations that were not detected by standard
sequencing were at levels between 20 to 30.5%. In total, only
57% of mutations at levels between 20 and 30.5% were identified
by standard sequencing in this study.
Low-abundance drug-resistant mutation profiles
Of the total 90 additional low-abundance DRMs detected by
ultra-deep sequencing in subjects, 62% were detected at levels 1 to
5%, and 38% were detected at levels 5 to 20% (Figure 1). Low-
abundance DRMs from all three antiretroviral classes were
detected. Eight of 22 subjects (36.5%) harbored low-abundance
mutations that imparted resistance to a single antiretroviral class; 6
of 22 subjects (27%) harbored resistance to two antiretroviral
classes, and 8 of 22 subjects (36.5%) harbored resistance to three
antiretroviral classes.
Low-abundance PI mutations were most commonly seen,
occurring in 18 of 22 subjects (82%); however the majority was
‘‘minor’’ IAS-USA PI mutations [23]. Low-abundance NRTI and
NNRTI mutations were also frequently detected, occurring in 17
of 22 subjects (73%) and 10 of 22 subjects (45%), respectively.
Table 1 lists all mutations detected in each subject by standard and
deep sequencing. The most common low-abundance NRTI
mutations detected were thymidine analog mutations (TAMs)
M41L, K70R, L210W, T215F/Y or K219E/Q. At least one of
these was detected in 11 of 22 subjects. T215F/Y was the most
common low-abundance TAMs detected. T215Y and T215F have
been shown to be associated with two distinct TAM pathways.
T215Y is associated with M41L, L210W, and sometimes D67N
(TAM-1 pathway), and T215F is associated with D67N, K70R,
and K219Q (TAM-2 pathway) [26,27]. T215Y was observed to
cluster with mutations in TAM-1 pathway (subjects #5 & 16) and
also with mutations in TAM-2 pathway (subjects #6 & 13). T215F
was either detected alone (subjects #11 & 15) or together with
mutations from both TAM-1 and TAM-2 pathways (subjects #1
& 3). Low-abundance M184V was detected in only one of 22
samples. Low-abundance NNRTI mutations were detected in 10
of 22 subjects (45%) by deep sequencing and in only 1 of 22
subjects by standard sequencing (subject #1 - K103N at 13.9%).
The most common low-abundance NNRTI mutations were
Figure 1. Mutation detection by standard versus ultra-deep sequencing according to mutation classes. A mean of 4 additional
mutations per subject were detected by ultra-deep sequencing. The difference in the number of mutations detected by the two methods were
statistically significant for NRTI (nucleotide/nucleoside reverse transcriptase inhibitor), NNRTI (non-nucleotide reverse transcriptase inhibitor), and PI
(protease inhibitor) mutations. Two-tailed p values and 95% confidence intervals were calculated from the paired Student T test.
doi:10.1371/journal.pone.0006079.g001
Minor HIV Resistant Variants
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samples.
Correlation of low-abundance DRMs with subjects’
antiretroviral histories
Current failing antiretroviral regimens were known for 19
subjects, and full antiretroviral histories were known for 14
subjects listed in table 1. None of the 10 subjects with low-
abundance TAMs (#1, 3, 4, 5, 6, 11, 13, 15, 16, 18) were on
zidovudine/stavudine-containing regimens at time of virologic
failure. Longitudinal antiretroviral histories were known for 9 of
these subjects, and all had prior zidovudine/stavudine exposure.
Subjects 5 and 6 had not been on zidovudine for 2 and 7 years,
respectively, yet TAMs were still being detected at low levels in
their blood. Low-abundance M184V was detected in only one
subject (#21) and was not detected in subjects who went off
lamivudine/emtricitabine. M184V was detected in 12 of 13
subjects who were on a failing regimen containing lamivudine/
emtricitabine and was predominantly present at levels .70%.
NNRTI mutations were detected in both low and high abundance
in subjects who were on NNRTI-containing regimens either at
time of virologic failure or in the past.
Overall, among the 19 subjects with known antiretroviral
regimens at time of virologic failure, low-abundance DRMs
correlated with the failing regimens in only 4 subjects (21%); all
were NNRTI mutations. By comparison, among the 14 subjects
with complete longitudinal antiretroviral histories, low-abundance
DRMs correlated with historical antiretroviral use in 11 subjects
(79%); most were TAMs (OR 13.75, 95% CI 2.5–74.3,
p=0.0016).
Impact of low-abundance DRMs on the resistance
burden in subjects failing ART
We used the Stanford HIV drug resistance scoring algorithm to
evaluate the extent to which additional low-abundance DRMs
detected by ultra-deep sequencing added to the resistance burden
in each subject. Seventeen of 22 subjects (77%) had additional low-
abundance DRMs that increased the subjects’ genotypic resistance
to at least one antiretroviral, and 11 of 22 subjects (50%) harbored
new resistance to at least one antiretroviral. For example, in
subject 16 the addition of K103N and V108I detected by ultra-
deep sequencing to the G190S detected by both methods changed
etravirine from intermediate resistance to high level resistance. In
the same sample, the addition of M41L, L210W and T215Y to the
M184V detected by both methods implied resistance to multiple
NRTIs, in addition to lamivudine.
Discussion
Our study demonstrates that low-abundance HIV DRMs are
commonly unrecognized in antiretroviral-experienced subjects at
time of virologic failure. DRMs at levels ,20% of viral quasi-
species made up 36% of the total number of mutations detected by
ultra-deep sequencing; the vast majority were undetected by
standard HIV genotyping. The additional low-abundance DRMs
increased the subjects’ genotypic resistance to at least one
antiretroviral drug in 77% of subjects and conferred new
resistance to at least one antiretroviral drug in 50% of subjects
when evaluated with the Stanford HIV drug resistance algorithm.
Our findings were in agreement with a prior study by Palmer and
colleagues who reported detection of additional 1 to 10 minority
drug-resistant variants from each of 26 treatment-experienced
subjects failing ART using single-genome sequencing [24]. Our
study using a new ultra-deep sequencing method provides
additional evidence that the burden of resistance in treatment-
experienced subjects at time of virologic failure is greater than that
reflected by standard HIV genotyping.
The concept that low-abundance HIV drug-resistant variants
can out-compete wild-type virus in presence of drug pressure is a
basic evolutionary tenet. When virologic failure is driven by
selection of drug-resistant virus, one would expect that mutant
variants conferring resistance to a failing antiretroviral regimen to
have a relative fitness advantage and to be detected in relatively
high abundance compared to wild-type virus. In addition to the
question of clinical relevance of low-abundance resistant virus,
other more fundamental questions about low-abundance drug-
resistant variants detected at time of virologic failure are a)
whether they represent accessory mutations or mutations present
in succession that increase the level of resistance to the current
failing regimens (in which case they would correlate with the
failing antiretroviral drug/s) or b) whether they are remnants of
resistant populations from prior failed therapy (in which case they
would correlate with historical antiretroviral use). The treatment
history correlation suggested different associations for different
low-abundance DRMs. We found that TAMs when detected at
low levels in subjects failing ART were highly correlated with
zidovudine/stavudine from prior exposure and not from the
current failing regimens. Some of the subjects harboring low-
abundance TAMs had not received zidovudine/stavudine for 2 to
7 years. The finding that drug-resistant variants can persist in the
circulation for much longer than previously known because of
more sensitive sequencing methods support further research using
these technologies to understand the mechanism of resistant viral
persistence and evolution in an infected person.
M184V was detected in 12 of 13 subjects who were on a failing
regimen containing lamivudine/emtricitabine, and all were
detected in relatively high abundance (generally .70%). In
contrast to TAMs, low-abundance M184V was not detected when
subjects were off lamivudine/emtricitabine. The lack of M184V
detection in these subjects may be due to M184V variants that
were either below the detection limit of this ultra-deep sequencing,
were never present, or were cleared from plasma compartment of
these subjects. M184V variants may wane from plasma relatively
faster than variants carrying other DRMs, probably due to the
fitness cost of M184V possessing virus [25,26].
NNRTI mutations are known to minimally impact viral fitness,
and this was observed in our study, in that the majority of subjects
(73%) with high-abundance NNRTI mutations were not on
NNRTI-containing regimens at time of virologic failure. By
comparison, low-abundance NNRTI mutations were seen equally
in subjects who were (4 of 9) or were not (5 of 9) on NNRTI-
containing regimens. Presence of low-abundance NNRTI muta-
tions in subjects who were not on NNRTI-containing regimens
may indicate longer elapsed time from last NNRTI use compared
to subjects with high-abundance NNRTI mutations. They may
also represent remnant mutations linked in the same genetic
backbone of a more favored mutational profile. Longitudinal
studies of patients with well-characterized treatment history who
stop NNRTI therapy using quantitative full-length sequencing
such as single genome sequencing would be desirable.
Interestingly, low-abundance mutations T215F and Y were
detected most commonly in subjects who were not on zidovudine/
stavudine-containing regimens. T215F and Y mutations require
two nucleotide substitutions (T215ACC to 215FTCC or 215YTAC),
which is a probable reason for their later appearance during the
course of zidovudine failure [27]. When zidovudine/stavudine
drug pressure is removed, T215F/Y-containing viral strains would
have to reverse-mutate in two different nucleotide positions to
Minor HIV Resistant Variants
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persistence in infected persons off zidovudine/stavudine therapy.
In this study, ultra-deep sequencing was able to detect a single
revertant T215N at 4.3% in subject #18, essentially capturing a
snapshot of evolving HIV strains that may have once been
thymidine analog resistant, and providing historical resistance
information that would not otherwise be possible by conventional
genotyping.
The finding that the additional low-abundance DRMs were
more correlated with historical antiretroviral use than to the failing
antiretroviral drugs (OR, 13.73; 95% CI, 2.5–74.3, p=0.0016) is
interesting and needs to be confirmed in larger studies, particularly
studies with well-characterized antiretroviral histories and with
longitudinal deep sequencing. Although the clinical significance of
these unrecognized mutations cannot be ascertained due to the
cross-sectional nature of our study, a potential clinical implication
here is that conventional genotype might be adequate for a subset
of patients with well-characterized antiretroviral treatment histo-
ries and known longitudinal HIV genotypes. However this clinical
scenario does not represent the majority of patients in clinical
practice. New sequencing technologies with better sensitivity such
as ultra-deep pyrosequencing method can provide important
historical resistance information that help clinicians planning
subsequent antiretroviral regimens for highly treatment-experi-
enced patients, especially for those whose antiretroviral treatment
histories and longitudinal HIV genotypes are not obtainable.
Studies have shown that cross-sectional HIV genotyping consis-
tently underestimates mutation rates compared to longitudinal
resistance data [28,29] and longitudinal resistance mutations
predict therapy failure better than cross-sectional resistance
mutations [30].
Our study has several limitations. First, the findings from the
clinical correlation are preliminary in nature due to the relatively
small sample size and inherent biases in any retrospective study.
Half of the study samples were from an adherence-focused clinical
trial [20] and were subjected to selection bias towards highly non-
adhered subjects, which might bias the number of minority drug-
resistant variants identified. The failing antiretroviral regimens
were known for most patients; however, complete antiretroviral
treatment histories were obtainable for only 14 subjects in the
study. For most subjects the precise treatment time tables and
subsequent clinical follow up were not obtainable due to the IRB
restriction on use of data that had already been collected in
another clinical study. Therefore larger confirmation studies with
well-characterized and longitudinal clinical histories are needed.
Second, an issue for all HIV genotyping technologies designed to
detect low-copy-number viral variants is that sensitivity is
dependent on the number of viral templates provided for cDNA
synthesis and clonal amplification [9]. Sampling of viral RNA
molecules from an extraction solution that follows Poisson
distribution is subjected to the stochastic effects of sampling
variation. These effects are lessened when the number of template
RNA molecules increases (typically .1000) [31]. Since current
HIV RNA extraction techniques may only recover up to 10% of
viral genomes from a plasma sample [32], only samples with
starting RNA copy numbers $10,000 can statistically account for
the sampling variation. One can still perform HIV genotyping of
low-copy-number samples (#3, 9, 11, 16, 18, 22 and 23); however,
the levels of mutations identified represent the proportion of
sequenced PCR amplicons containing the mutation and may not
represent the actual proportion in a plasma sample. We used
140 ml extraction volume because that was the standard plasma
volume used for standard sequencing. To obtain a better
representative sampling of HIV variants in low-copy-number
samples, larger volume extractions from plasma samples would be
required. Lastly, ultra-deep sequencing is highly sensitive but more
labor-intensive than population sequencing, and the technology
will need to be clinically validated before being considered for
clinical use.
Despite above limitations, we can conclude that low-abundance
HIV drug-resistant mutations commonly go unrecognized in
treatment-experienced persons who experience virologic failure.
The majority of the unrecognized resistant mutations are
clinically-relevant, and they increased the overall burden of
resistance in these subjects. The clinical significance of these
unrecognized mutations cannot be ascertained due to the cross-
sectional nature of our study; however, we can conclude that the
majority of unrecognized resistant mutations correlate with
historical antiretroviral use rather than to the failing antiretroviral
drugs. A potential clinical implication is that ultra-deep sequencing
can provide important historical resistance information that help
clinicians planning subsequent antiretroviral regimens for highly
treatment-experienced patients, particularly for a significant
proportion of patients in clinical practice whom treatment histories
and longitudinal HIV genotypes are not available.
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